Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis

Tuberculosis Clinical Trial

— TB-HAART  

Official title:

Randomized Clinical Trial to Determine the Most Appropriate Time to Start HIV Treatment in HIV & TB Coinfected Adults Being Treated for Tuberculosis.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01315301
• Other study ID #: SWE-2007-270
• Status: Recruiting
• Phase: N/A
• First received: March 14, 2011
• Last updated: March 14, 2011
• Start date: August 2008
• Est. completion date: March 2012

Study information

• Verified date: March 2011
• Source: Karolinska Institutet
• Contact: Wondwossen Amogne, MD
• Phone: +251911406179
• Email: wonamogne[@]yahoo.com
• Is FDA regulated: No
• Health authority: Ethiopia: Drug Administration and Control Authority
• Study type: Interventional

Clinical Trial Summary

Aim of the study is to determine optimal time to initiate anti-retroviral therapy in HIV/TB co-infected patients who recently started treatment for Tuberculosis by comparing immediate versus deferred initiation of HAART.

The study will address the following questions;

• Is it possible to reduce mortality rate and increase survival by early initiation of HAART during TB treatment with out compromising for adverse drug reaction, toxicity and immune reconstitution syndrome?

• What is the risk/ benefit ratio between immediate versus deferred initiation of HAART during TB treatment with respect to safety/efficacy of TB and HIV co-treatment?

• When is the most appropriate time to start HAART during TB treatment?

Description:

The study intends to determine the optimal time to start ART by comparing three treatment strategies of ART initiation in HIV/TB co-infected patients. Four hundred fifty newly diagnosed HIV infected patients with active TB and CD4 cell count < 200 cells/mm3 will be prospectively recruited to be assigned randomly in parallel into one of the three treatment groups (n=150 in each group) and HAART will be started at different time points as described below with extensive counseling and adherence support.

• Arm-A (Immediate Treatment Group): Receipt of antiretroviral therapy one week after starting anti-TB treatment.

• Arm-B (Deferred Treatment Group-1): Antiretroviral therapy will be initiated at the 4th week of starting anti-TB treatment (in the middle of the intensive phase TB treatment).

• Arm-C (Deferred Treatment Group-2): Antiretroviral therapy will be initiated at the 8th week of starting anti-TB treatment (after completion of the intensive phase of TB treatment).

Study Design: Interventional, prospective, randomized, open-label three-armed trial with no placebo, Active control, parallel assignment, safety and efficacy study.

Study population: Previously untreated HIV-infected adult patients with TB and CD4 cell counts < 200/mm3 at the time of TB diagnosis.

Expected Total Enrollment = 450

Treatment: Patients will receive first-line preferred regimen for patients with TB and HIV coinfection (rifampicin containing short course TB treatment and efavirenz-containing HAART regimen. The intensive phase of anti-TB therapy consists of 2 months treatment with Rifampicin, Isoniazid, Pyrazinamide and Ethambutol followed by the continuation phase with Isoniazid and Rifampicin daily for 4 months under Directly Observed Therapy (DOTS). After the initiation of TB treatment, patients in Arm-A, Arm-B and Arm-C will start EFV-containing HAART regimen (efavirenz + Lamivudine (3TC) + Stavudine (d4T) after one week, in the middle(at 4th week) and at the end (8th week) of the intensive phase TB treatment respectively. Primar prophylaxis with cotrimoxazole will be offered to all patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: March 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed ART naive HIV infected patients and age > 18 years old

• Newly diagnosed smear +ve PTB cases (abnormal CXR and at least one sputum sample +ve for AFB)

• Newly diagnosed smear -ve PTB cases (CXR consistent with active TB plus at least two sputum specimens negative for AFB and decision by the physician to treat for TB or smear negative for AFB but culture positive cases)

• Tissue biopsy or FNAC results consistent with the diagnosis of tuberculosis

• CD4 cell count < 200/mm3 at the time of TB diagnosis

• Residence in Addis Ababa, Ethiopia

• Ability to give signed written/thumb sign informed consent

Exclusion Criteria:

• Pregnancy and breast-feeding women

• Patients who received anti TB therapy with in the past two years

• Patients who have previous treatment experience with antiretroviral therapy

• Severely ill patients Karnofsky performance status score < 40

• Baseline Hgb < 8 gms/dL

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Immunologic Deficiency Syndromes
• Tuberculosis

Intervention

Other:
• Comparison of different treatment strategies
600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
• Comparison of different treatment strategies
600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
• Comparison of different treatment strategies
600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.

Locations

Country	Name	City	State
Ethiopia	Tikur Anbessa (Black Lion) Hospital	Addis Ababa

Sponsors (2)

Lead Sponsor	Collaborator
Karolinska Institutet	Addis Ababa University

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mortality	all cause mortality	24 weeks	Yes
Secondary	Tuberculosis-Immune Reconstitution Inflammatory Syndrome		24 weeks	Yes
Secondary	New AIDS defining clinical events		24 weeks	Yes
Secondary	Drug Induced Liver toxicity		24 weeks	Yes
Secondary	Virologic success	Proportion of patients with Virologic success defined as achieving a viral load of < 50 HIV-1 RNA copies/mL within 6 months of starting therapy	24 weeks	No